Peptide reference
What each compound is, what research has actually measured, and where it stands with FDA and WADA. Sourced, dated, and free of benefit claims.
| Compound | What it is | Status |
|---|---|---|
| Retatrutide | Investigational GIP, GLP-1 and glucagon receptor triple agonist (peptide) | Investigational, not approved |
| Tirzepatide | GIP and GLP-1 receptor dual agonist (peptide) | FDA-approved drug exists |
| Semaglutide | GLP-1 receptor agonist (peptide) | FDA-approved drug exists |
| BPC-157 | Synthetic 15-amino-acid peptide (not an approved drug) | Not an approved drug |
| TB-500 | Synthetic peptide related to thymosin beta-4 (not an approved drug) | Not an approved drug |
| GHK-Cu | Copper-binding tripeptide (cosmetic ingredient; not an approved drug) | Not an approved drug |
| CJC-1295 / Ipamorelin | GHRH analog plus growth hormone secretagogue (neither approved) | Not an approved drug |
| MOTS-c | Mitochondrial-derived peptide (not an approved drug) | Not an approved drug |
| NAD+ | Coenzyme (not a peptide; not an approved injectable drug) | Not an approved drug |
| Tesamorelin | GHRH analog (peptide) | FDA-approved drug exists |
| Sermorelin | GHRH(1-29) analog (peptide) | Approved product discontinued |